Good
Mostly Aligned
Patient Risk:
Low
Summary
The provided AI claim is largely consistent with the FDA label excerpts for ATACAND’s fetal toxicity warning and discontinuation when pregnancy is detected. Minor product-scope overreach (mentions ATACAND/ATACAND HCT together despite the evaluation focusing on ATACAND) slightly reduces precision but does not contradict the supported fetal-toxicity language shown.
Category Scores
Accurate Statements
ATACAND can cause fetal harm/fetal toxicity when administered to a pregnant woman, via drugs that act on the renin-angiotensin system in the second and third trimesters, leading to oligohydramnios and neonatal adverse outcomes.
Supported by FDA label excerpts in 5.1 Fetal Toxicity and 8.1 Pregnancy describing fetal harm, RAS effects in 2nd/3rd trimesters, oligohydramnios, and neonatal adverse reactions (e.g., anuria, hypotension, renal failure, death).
ATACAND should be discontinued as soon as pregnancy is detected.
Supported by FDA label excerpts in 5.1 Fetal Toxicity and 8.1 Pregnancy: “When pregnancy is detected, discontinue ATACAND as soon as possible.”
Unsupported Statements
“ATACAND/ATACAND HCT should be discontinued when pregnancy is detected.”
The evaluation/product focus provided is ATACAND, and the label excerpts supplied for discontinuation are for ATACAND. While ATACAND HCT is also discussed elsewhere in the provided label excerpts (fetal toxicity), the AI statement is not limited to ATACAND and therefore is less precisely supported for the combined ATACAND/ATACAND HCT phrasing.
Contradictions
Important Omissions
No explicit inclusion of the FDA label’s recommendation for monitoring (e.g., performing serial ultrasound examinations; considering alternative treatment if oligohydramnios is observed) and neonatal observation/support details described in 8.1.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The core pregnancy fetal-toxicity warning and discontinuation instruction are supported by the provided FDA label excerpts. Precision regarding ATACAND vs ATACAND HCT is slightly diluted, and some monitoring details in the label were omitted, but no contradictory safety instruction was provided.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Minor product-scope imprecision: the claim merges “ATACAND/ATACAND HCT” despite the supplied evaluation focusing on ATACAND.
Suggested Improvement
Restrict the claim to ATACAND (or explicitly cite/discuss ATACAND HCT with matching label sections) and, if completeness is needed, include the label’s monitoring/infant observation recommendations from 8.1.